By Ben GlickmanShares of Cerevel Therapeutics rose Wednesday after AbbVie announced it would acquire the company for about $8.7 billion. Cerevel shares were up 14%, to $42, in after-hours trading Wednesday, following a 3.8% rise at Wednesday's close. Shares are up 17% this year.

Source: Wall Street Journal December 07, 2023 09:49 UTC